Timur Mitin

Timur Mitin

Auto-generated profile, based on publicly available information

Timur Mitin

Department of Radiation Medicine, Oregon Health & Science University, Portland, OR

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TMTimur Mitin
Timur Mitin
AZAnthony L. Zietman
Anthony L. Zietman
Proton beam therapy, the most common form of heavy-particle radiation therapy, is not a new invention, but it has gained considerable public attention because of the high cost of installing and operating the rapidly increasing number of treatment centers. This article reviews the physical properties of proton beam therapy and focuses on the up-to-date clinical evidence comparing proton beam therapy with the more standard and widely available radiation therapy treatment alternatives. In a cost-conscious era of health care, the hypothetical benefits of proton beam therapy will have to be supported by demonstrable clinical gains. Proton beam therapy represents, through its scale and its cost, a battleground for the policy debate around managing expensive technology in modern medicine.

13 April 2016 in Cancer
Verified
Journal Article
Open access
PDF file
HSHelmneh M. Sineshaw
Helmneh M. Sineshaw
AJAhmedin Jemal
Ahmedin Jemal
CTCharles R. Thomas
Charles R. Thomas
TMTimur Mitin
Timur Mitin
BACKGROUND: In the United States, neoadjuvant chemoradiotherapy (NACRT) is widely accepted as the standard of care in the treatment of patients with locally advanced rectal cancer. In the current study, the authors attempted to examine patterns of treatment in the United States over the past decade.METHODS: Using the National Cancer Data Base, a total of 66,197 patients who were diagnosed with American Joint Committee on Cancer stage II to III rectal adenocarcinoma and treated between 2004 and 2012 were identified. The authors described trends in the receipt of treatment for 3 time periods (2004‐2006, 2007‐2009, and 2010‐2012) and analyzed 5‐year overall survival probabilities for 28,550 patients treated between 2004 and 2007.RESULTS: Receipt of NACRT increased significantly from 42.9% between 2004 and 2006 to 50.0% between 2007 and 2009, and to 55.0% between 2010 and 2012 (P < .0001). In contrast, the use of adjuvant chemoradiotherapy (CRT) decreased from 16.7% between 2004 and 2006 to 10.5% between 2007 and 2009, and to 6.7% between 2010 and 2012 (P < .0001). Similarly, the use of surgery alone decreased from 13.1% between 2004 and 2006 to 8.7% between 2010 and 2012 (P < .0001). Older age, the presence of comorbidities, larger primary tumor size, lymph node involvement, not being of non‐Hispanic white race/ethnicity, lack of private insurance, and treatment at a facility that did not have a high case volume were associated with a significantly lower possibility of receiving NACRT. The 5‐year overall survival rates for patients treated with NACRT, surgery and adjuvant CRT, surgery alone, and definitive CRT were 72.4%, 70.9%, 44.9%, and 48.8%, respectively.CONCLUSIONS: The use of NACRT before surgery in US patients with rectal cancer has substantially increased over the past decade. However, only approximately one‐half of patients currently receive this standard therapy, which could be explained in part by socioeconomic factors. Trimodality therapy is associated with the best outcomes for these patients. Cancer 2016;122:1996–2003. © 2016 American Cancer Society.

9 March 2017 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
TMTimur Mitin
Timur Mitin
CEC. Kristian Enestvedt
C. Kristian Enestvedt
AJAhmedin Jemal
Ahmedin Jemal
HSHelmneh M. Sineshaw
Helmneh M. Sineshaw
Background: There are no randomized data to guide clinicians treating patients with gallbladder cancer (GBC). Several retrospective studies reported the survival benefits of adjuvant radiotherapy (RT) and chemoradiation (CRT). In this paper, we examine whether these publications have impacted the utilization of adjuvant therapies and whether their survival benefits are evident in a contemporary cohort of patients. Methods: Using the National Cancer Data Base, we identified 5029 patients diagnosed with T1‐3N0‐1 GBC and treated with surgical resection from 2005 to 2013. We described trends in receipt of adjuvant treatments for three time periods (2005–2007, 2008–2010, 2011–2013) and calculated three-year overall survival (OS) probabilities for 2989 patients treated in 2005–2010. All statistical tests were two-sided. Results: The percentage of patients who received no adjuvant treatments was unchanged from 2005 to 2013. Adjuvant RT decreased from 4.2% to 1.7% (P < .001), adjuvant chemotherapy increased from 8.3% to 13.8% (P < .001), and adjuvant CRT remained stable at 15.9% (P = .98). Adjuvant treatments were associated with improved three-year OS, with adjusted hazard ratio of 0.47 (95% confidence interval [CI] = 0.39 to 0.58) for CRT, 0.77 (95% CI = 0.61 to 0.97) for chemotherapy, and 0.63 (95% CI = 0.44 to 0.92) for RT. Adjuvant CRT was associated with improved survival in all categories, except T1N0, and in patients with negative and positive margins. Conclusion: Over the past decade there was no increase in the utilization of adjuvant therapies in the United States for patients with resected GBC. Adjuvant therapy is associated with statistically significantly improved three-year OS. This analysis should form the basis for current clinical recommendations and support future prospective trials.

1 January 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
TMTimur Mitin
Timur Mitin
AGAsha George
Asha George
AZAnthony L. Zietman
Anthony L. Zietman
NHNiall M. Heney
Niall M. Heney
DKDonald S. Kaufman
Donald S. Kaufman
WSWilliam U. Shipley
William U. Shipley

1 January 2019 in Clinical Lung Cancer
Verified
Journal Article
Closed access
MFMatthew J. Farrell
Matthew J. Farrell
JYJehan B. Yahya
Jehan B. Yahya
CDCatherine Degnin
Catherine Degnin
YCYiyi Chen
Yiyi Chen
JHJohn M. Holland
John M. Holland
TMTimur Mitin
Timur Mitin

1 August 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
AJAditya Jain
Aditya Jain
JLJia Luo
Jia Luo
YCYiyi Chen
Yiyi Chen
MHMark A. Henderson
Mark A. Henderson
CTCharles R. Thomas
Charles R. Thomas
TMTimur Mitin
Timur Mitin